Dr Vikesh Chhabria
Lecturer
School of Biosciences
Publication
2020
- Zhou, Z., Chhabria, V., D'Emanuele, A. and Forbes, R. T. 2020. Worm-like micelles of triblock copolymer of ethylene oxide and styrene oxide characterised using light scattering and Taylor dispersion analysis. International Journal of Pharmaceutics 588, article number: 119758. (10.1016/j.ijpharm.2020.119758)
- Patil-Sen, Y., Torino, E., De Sarno, F., Ponsiglione, A. M., Chhabria, V., Ahmed, W. and Mercer, T. 2020. Biocompatible superparamagnetic core-shell nanoparticles for potential use in hyperthermia-enabled drug release and as an enhanced contrast agent. Nanotechnology 31(37), article number: 375102. (10.1088/1361-6528/ab91f6)
- Wychowaniec, J. K. et al. 2020. Aromatic stacking facilitated self-assembly of ultrashort ionic complementary peptide sequence: β-sheet nanofibers with remarkable gelation and interfacial properties. Biomacromolecules 21(7), pp. 2670-2680. (10.1021/acs.biomac.0c00366)
2018
- Patil-Sen, Y. and Chhabria, V. 2018. Superparamagnetic iron oxide nanoparticles for magnetic hyperthermia applications. In: NanoBioMaterials. New York, US: Taylor & Francis, pp. Chapter 13., (10.1201/9781351138666-13)
2017
- Narain, A., Asawa, S., Chhabria, V. and Patil-Sen, Y. 2017. Cell membrane coated nanoparticles: next-generation therapeutics. Nanomedicine 12(21), pp. 2677–2692. (10.2217/nnm-2017-0225)
2016
- Chhabria, V. and Beeton, S. 2016. Development of nanosponges from erythrocyte ghosts for removal of streptolysin-O from mammalian blood. Nanomedicine 11(21), pp. 2797–2807. (10.2217/nnm-2016-0180)
Articles
- Zhou, Z., Chhabria, V., D'Emanuele, A. and Forbes, R. T. 2020. Worm-like micelles of triblock copolymer of ethylene oxide and styrene oxide characterised using light scattering and Taylor dispersion analysis. International Journal of Pharmaceutics 588, article number: 119758. (10.1016/j.ijpharm.2020.119758)
- Patil-Sen, Y., Torino, E., De Sarno, F., Ponsiglione, A. M., Chhabria, V., Ahmed, W. and Mercer, T. 2020. Biocompatible superparamagnetic core-shell nanoparticles for potential use in hyperthermia-enabled drug release and as an enhanced contrast agent. Nanotechnology 31(37), article number: 375102. (10.1088/1361-6528/ab91f6)
- Wychowaniec, J. K. et al. 2020. Aromatic stacking facilitated self-assembly of ultrashort ionic complementary peptide sequence: β-sheet nanofibers with remarkable gelation and interfacial properties. Biomacromolecules 21(7), pp. 2670-2680. (10.1021/acs.biomac.0c00366)
- Narain, A., Asawa, S., Chhabria, V. and Patil-Sen, Y. 2017. Cell membrane coated nanoparticles: next-generation therapeutics. Nanomedicine 12(21), pp. 2677–2692. (10.2217/nnm-2017-0225)
- Chhabria, V. and Beeton, S. 2016. Development of nanosponges from erythrocyte ghosts for removal of streptolysin-O from mammalian blood. Nanomedicine 11(21), pp. 2797–2807. (10.2217/nnm-2016-0180)
Book sections
- Patil-Sen, Y. and Chhabria, V. 2018. Superparamagnetic iron oxide nanoparticles for magnetic hyperthermia applications. In: NanoBioMaterials. New York, US: Taylor & Francis, pp. Chapter 13., (10.1201/9781351138666-13)
Research
1.) An alternative to antibiotics, development of cell membrane coated nanoparticles as a detoxification platform- Bacteria can cause many different types of infections. Virulence factors e.g. adherence proteins, biofilm formation, endotoxins and exotoxins allow invasion by bacteria and cause infections such as respiratory, urinary, and intestinal and blood stream infections. If left untreated they can lead to a condition known as sepsis. Sepsis is a whole body inflammatory response that can be fatal. Exotoxins, such as pore forming toxins are one of the virulence factors secreted by bacteria that are responsible for causing sepsis. Current treatment and management of sepsis includes surgical drainage of fluids, blood transfusions and administration of antibiotics. Sepsis is a rapid onset with an increased mortality rate of 8% per hour. This means that prompt treatment is imperative and due to the increase in antibiotic resistance, treatment has become more difficult.
The aim of this study is to develop biomimetic nanosponges from mammalian erythrocyte ghosts, as a potential treatment for toxin related sepsis. The nanosponges had the ability to absorb streptolysin-O and a-haemolysin.
2.) Protein Aggregation screening of biopharmaceuticals - a three year million pound innovate UK funded project in collaboration with GSK, AstraZeneca, Fujifilm Diosynth, CPI, Malvern Pananalytical and Paraytec, developing novel analytics to characterize the aggregation potential of biologics (monoclonal antibodies, vaccine candidates, virus like particles, antibody-drug conjugates and advanced therapy medicinal products). As part of this project, we developed a novel ex-vivo method for protein aggregation screening of biopharmaceuticals, which is of great value to the end users within the consortium. Therefore, the method has been kept under an inventional disclosure. This project not only involved industrial collaborations, but partnerships with other external and inter-departmental research groups synthesizing various other complex delivery systems such as Lipid-silica-SPIONS, Liposomes, Solid lipid nanoparticles and Dendrimers, to encapsulate poorly soluble drugs for delivery in several in-vitro disease states.
Teaching
Delivered, planned and assessed components of all year undergraduate biomedical sciences and pharmacy modules such as immunology, biochemistry, clinical microbiology, industrial microbiology, infection and immunity, lab skills, pathology, pharmaceutical sciences, physiology, haematology, drug discovery and delivery, and pharmacology.
Biography
Having completed my undergraduate degree in Biomedical sciences at the University of Central Lancashire, I was offered a partly funded PhD in Pharmaceutical Microbiology, synthesizing novel nanoformulations using mammalian erythrocytes to mop up bacterial pore-forming toxins that cause severe sepsis, constituting aspects of microbiology, biochemistry and pharmaceutical sciences.
In 2016, I was appointed an associate lecturer in clinical pharmacology which involved delivering, planning and assessing components of all year undergraduate biomedical sciences and pharmacy modules such as immunology, biochemistry, clinical microbiology, industrial microbiology, infection and immunity, lab skills, pathology, pharmaceutical sciences, physiology, haematology, drug discovery and delivery, and pharmacology.
I am an experienced research scientist who works in the area of protein aggregation screening of biopharmaceuticals. In 2017 I was offered a three-year postdoctoral research associate position in Professor Robert Forbes's Lab, working on developing novel tools for protein aggregation screening of biopharmaceutical candidates, a million pound innovate UK project in collaboration with GSK, AstraZeneca, Fujifilm Diosynth, CPI, Malvern Pananalytical and Paraytec.
In 2021, I was appointed a lecturer in biomedical Sciences at Cardiff University. I am the Module lead for BI1002 (Structure and Function of living organisms), ED&I Lead student facing and Disability Lead.
Honours and awards
01/2018 Award for the best poster at the International Workshop on Nanomaterials in Health/Medicine.
01/2018 Award for the best poster at the 3rd International Symposium on Nanoparticles/Nanomaterials and Applications.
10/2023 Exploring Bioscience Symposium- Biochemical Society LA grant awarded 200£
08/2024 Biochemical Society’s Sponsored Seminar Series Grant- Bridging Silos: Cross Disciplinary Approaches to AI in the Biosciences
Professional memberships
Local Ambassador for the Biochemical Society.
Contact Details
+44 29208 74111
Sir Martin Evans Building, Museum Avenue, Cardiff, CF10 3AX